U.S. Banks Stock News

NYSE:DOLE
NYSE:DOLEFood

Dole Index Inclusion Meets European Acquisition And Capital Return Plans

Dole plc (NYSE:DOLE) is set to be added to the MSCI ACWI Investable Market Index, MSCI ACWI Small Cap Index, and MSCI USA Small Cap Index. The index changes are scheduled to take effect on May 29, 2026. The inclusion may influence Dole's visibility with index-tracking funds and passive investors. Dole, trading at $14.1, is coming into these index additions with a mixed return profile. The stock is down 5.2% over the past week, down 7.1% over the past 30 days, and down 3.6% year to date,...
NYSE:FLNG
NYSE:FLNGOil and Gas

FLEX LNG NYSE Move And Higher Guidance Test High Dividend Story

FLEX LNG plans to delist from the Oslo Stock Exchange and move to exclusive trading on the NYSE under ticker NYSE:FLNG. The company has raised its full year 2026 financial guidance and expanded its long term charter backlog. New and extended charter contracts now secure 91% of available vessel days for 2026. FLEX LNG, which last closed at $32.13, has shown strong share price performance, up 30.2% year to date and 45.7% over the past year. Over 5 years, the stock is up 280.2%, reflecting how...
NYSE:KODK
NYSE:KODKTech

A Look At Kodak (KODK) Valuation As New Hubble Connected Smart Family Products Are Announced

Eastman Kodak (KODK) is in focus after Hubble Connected unveiled plans for a new line of Kodak licensed smart family products, set to debut at the ABC Kids Expo in Las Vegas. See our latest analysis for Eastman Kodak. The licensing news lands after a mixed stretch in the stock, with the share price down 26.37% over the past 30 days but up 26.34% over 90 days and a 49.31% one year total shareholder return, suggesting momentum has been choppy rather than moving in a single direction. If this...
NYSE:DAN
NYSE:DANAuto Components

Dana (DAN) Discontinued Ops Windfall Tests Bullish Margin Repair Narrative

Dana (DAN) opened Q1 2026 with total revenue of US$1,868 million and a basic EPS loss of US$0.17, giving investors a fresh read on how top line scale is translating into the bottom line. Over the past year, the company has seen quarterly revenue move from US$1,781 million in Q1 2025 to US$1,868 million in Q1 2026. Basic EPS has ranged from a loss of US$1.37 in Q4 2024 to a loss of US$0.35 in Q4 2025 and a loss of US$0.17 in the latest quarter. This progression sets up a story that is focused...
NasdaqGM:MIRM
NasdaqGM:MIRMBiotechs

Mirum’s VISTAS Success And What It Could Mean For MIRM Shareholders

Mirum Pharmaceuticals reported positive topline VISTAS Phase 2b results for volixibat in primary sclerosing cholangitis related cholestatic pruritus. The trial showed a robust, clinically meaningful improvement in itch symptoms for PSC patients, who currently have no approved treatment options. Following the data, Mirum has a pre NDA meeting scheduled and plans to file for regulatory approval for volixibat. For investors tracking Mirum Pharmaceuticals, ticker NasdaqGM:MIRM, this update sits...
NYSE:EVR
NYSE:EVRCapital Markets

Evercore’s Standout Quarter And Senior Equities Hire Reshape Growth Outlook

Evercore (NYSE:EVR) reported an exceptional first quarter, delivering the fastest revenue growth among its investment banking peers. The company significantly exceeded analyst expectations for the period. Evercore also strengthened its Equities division with the hire of a highly experienced industry veteran to a senior role. Evercore enters this news cycle with the stock at $333.56 and a 1 year return of 39.7%. Despite this, the share price is down 5.0% year to date, 8.1% over the past...